Intrust Bank NA Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN)

Intrust Bank NA trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,189 shares of the medical research company’s stock after selling 251 shares during the quarter. Intrust Bank NA’s holdings in Amgen were worth $2,359,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after buying an additional 165,636 shares during the period. Northern Trust Corp boosted its holdings in shares of Amgen by 3.8% in the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after buying an additional 255,463 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Amgen by 1.1% during the third quarter. Bank of New York Mellon Corp now owns 5,437,182 shares of the medical research company’s stock worth $1,461,297,000 after purchasing an additional 61,528 shares during the period. Royal Bank of Canada boosted its holdings in shares of Amgen by 11.4% during the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock worth $1,365,213,000 after purchasing an additional 518,689 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Amgen by 15.9% during the third quarter. Invesco Ltd. now owns 3,356,359 shares of the medical research company’s stock worth $902,055,000 after purchasing an additional 459,340 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMGN. TD Cowen dropped their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Oppenheimer restated an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Truist Financial restated a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Raymond James started coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating for the company. Finally, Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $297.40.

Amgen Stock Up 2.4 %

NASDAQ:AMGN traded up $6.40 during trading hours on Monday, reaching $276.38. 2,676,509 shares of the stock were exchanged, compared to its average volume of 2,806,966. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a 50 day moving average of $275.10 and a 200 day moving average of $281.51. The stock has a market cap of $148.24 billion, a PE ratio of 21.62, a PEG ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.09 EPS. On average, equities analysts expect that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.26%. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.